Seaport Therapeutics, Inc. $SPTX Position Lessened by Aberdeen Group plc

Aberdeen Group plc decreased its stake in shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX – Free Report) by 13.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 267,678 shares of the company’s stock after selling 42,677 shares during the quarter. Aberdeen Group plc’s holdings in Seaport Therapeutics were worth $5,399,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of SPTX. HighTower Advisors LLC bought a new stake in Seaport Therapeutics in the second quarter valued at $362,000. Squarepoint Ops LLC bought a new stake in Seaport Therapeutics in the 2nd quarter valued at about $538,000. Alps Advisors Inc. raised its stake in Seaport Therapeutics by 30.5% during the 3rd quarter. Alps Advisors Inc. now owns 70,921 shares of the company’s stock worth $1,430,000 after buying an additional 16,593 shares during the period. State Street Corp acquired a new position in Seaport Therapeutics during the 2nd quarter worth approximately $1,448,000. Finally, Alyeska Investment Group L.P. bought a new position in Seaport Therapeutics in the second quarter worth approximately $1,629,000.

Seaport Therapeutics Stock Up 0.1%

Shares of SPTX opened at $18.32 on Friday. Seaport Therapeutics, Inc. has a 12-month low of $14.85 and a 12-month high of $28.38. The firm’s 50-day simple moving average is $19.97.

Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.09. On average, equities analysts forecast that Seaport Therapeutics, Inc. will post -4.30 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SPTX. Weiss Ratings raised shares of Seaport Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, November 4th. UBS Group reissued a “buy” rating on shares of Seaport Therapeutics in a research report on Thursday, October 8th. Canaccord Genuity Group assumed coverage on Seaport Therapeutics in a research report on Wednesday, October 14th. They issued a “buy” rating and a $28.00 price objective on the stock. Raymond James Financial began coverage on shares of Seaport Therapeutics in a research note on Friday, September 25th. They set a “strong-buy” rating and a $46.00 price target for the company. Finally, JonesTrading assumed coverage on Seaport Therapeutics in a research note on Wednesday, August 26th. They set a “buy” rating and a $32.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.12.

Read Our Latest Analysis on SPTX

Insider Transactions at Seaport Therapeutics

In related news, Director Denice Torres purchased 5,000 shares of the business’s stock in a transaction on Tuesday, November 3rd. The stock was acquired at an average price of $19.86 per share, with a total value of $99,300.00. Following the purchase, the director directly owned 5,000 shares in the company, valued at approximately $99,300. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

About Seaport Therapeutics

(Free Report)

Seaport Therapeutics is a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric disorders. The company uses its Glyph platform to design oral prodrugs intended to improve the delivery of therapies that can be difficult to administer or absorb by mouth. Its pipeline includes SPT-300, an oral prodrug of allopregnanolone being developed for depression. Seaport was launched in 2024 and is headquartered in Boston, Massachusetts. Its leadership includes founder and Chief Executive Officer Daphne Zohar.

Featured Stories

Want to see what other hedge funds are holding SPTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seaport Therapeutics, Inc. (NASDAQ:SPTX – Free Report).

Institutional Ownership by Quarter for Seaport Therapeutics (NASDAQ:SPTX)

Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.